WO2012058666A3 - Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy - Google Patents

Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy Download PDF

Info

Publication number
WO2012058666A3
WO2012058666A3 PCT/US2011/058558 US2011058558W WO2012058666A3 WO 2012058666 A3 WO2012058666 A3 WO 2012058666A3 US 2011058558 W US2011058558 W US 2011058558W WO 2012058666 A3 WO2012058666 A3 WO 2012058666A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
water
cancer therapy
compound
Prior art date
Application number
PCT/US2011/058558
Other languages
French (fr)
Other versions
WO2012058666A2 (en
Inventor
Fengzhi Li
Xiang Ling
Shousong Cao
Original Assignee
Health Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US40799610P external-priority
Application filed by Health Research, Inc. filed Critical Health Research, Inc.
Priority to EP11837250.7A priority Critical patent/EP2632264B1/en
Priority to CA2816418A priority patent/CA2816418C/en
Priority to CN201180063530.5A priority patent/CN103442565B/en
Priority to US13/881,785 priority patent/US9422303B2/en
Publication of WO2012058666A2 publication Critical patent/WO2012058666A2/en
Publication of WO2012058666A3 publication Critical patent/WO2012058666A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Provided are compositions, methods of making the compositions, and methods of using the compositions. The compositions can be provided as pharmaceutical preparations for use in disease treatment, such as cancer therapy. The compositions include novel pharmaceutical preparations which contain effective concentrations of a chemical compound. One compound used is 10H-1,3-Dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2-b] quinoline-8,11(7H,12H)-dione, 7-ethyl-7- hydroxy-, (S)-. The invention also provides methodologies for preparing pharmaceutical preparations for use in intravenous and oral pharmaceutical preparations that contain drug compounds that are difficult to dissolve in water.
PCT/US2011/058558 2010-10-29 2011-10-31 Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy WO2012058666A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP11837250.7A EP2632264B1 (en) 2010-10-29 2011-10-31 Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy
CA2816418A CA2816418C (en) 2010-10-29 2011-10-31 Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy
CN201180063530.5A CN103442565B (en) 2010-10-29 2011-10-31 Use non-water soluble compounds new formulation and the method for the compound FL118 preparation for treatment of cancer
US13/881,785 US9422303B2 (en) 2010-10-29 2011-10-31 Formulations of water-insoluble chemical compounds and methods of using a formulation of compound FL118 for cancer therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40799610P 2010-10-29 2010-10-29
US61/407,996 2010-10-29

Publications (2)

Publication Number Publication Date
WO2012058666A2 WO2012058666A2 (en) 2012-05-03
WO2012058666A3 true WO2012058666A3 (en) 2013-01-10

Family

ID=45994848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/058558 WO2012058666A2 (en) 2010-10-29 2011-10-31 Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy

Country Status (5)

Country Link
US (1) US9422303B2 (en)
EP (1) EP2632264B1 (en)
CN (1) CN103442565B (en)
CA (1) CA2816418C (en)
WO (1) WO2012058666A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3122754A4 (en) * 2014-03-26 2018-02-21 Canget Biotekpharma, LLC Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease
KR102349925B1 (en) * 2020-07-16 2022-01-12 주식회사 피노바이오 A compound containing FL118 drug and immunoconjugates using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0556585A2 (en) * 1992-01-24 1993-08-25 Takeda Chemical Industries, Ltd. Condensed camptothecin derivatives their production and use as antitumor agents
US6653319B1 (en) * 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
AU2001240024A1 (en) * 2000-03-31 2001-10-15 Supergen, Inc. Camptothecin complexes
DE60115044T2 (en) 2000-06-30 2006-08-03 Inex Pharmaceuticals Corp., Burnaby Liposomal antineoplastic drugs and their uses
US6509027B2 (en) * 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
WO2008073201A2 (en) 2006-11-10 2008-06-19 Health Research Inc. Compositions and methods for identifying agents that alter expression of survivin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0556585A2 (en) * 1992-01-24 1993-08-25 Takeda Chemical Industries, Ltd. Condensed camptothecin derivatives their production and use as antitumor agents
US6653319B1 (en) * 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM [online] 27 March 2005 (2005-03-27), XP003031894, retrieved from NCBI Database accession no. CID 437971 *

Also Published As

Publication number Publication date
CN103442565B (en) 2016-08-10
EP2632264A4 (en) 2014-04-23
CN103442565A (en) 2013-12-11
EP2632264A2 (en) 2013-09-04
EP2632264B1 (en) 2019-10-02
CA2816418C (en) 2020-05-26
US20140066470A1 (en) 2014-03-06
US9422303B2 (en) 2016-08-23
WO2012058666A2 (en) 2012-05-03
CA2816418A1 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
GB201104267D0 (en) Pyrrolopyridineamino derivatives
MX2017009841A (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy.
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
NZ711948A (en) Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
WO2006099169A3 (en) Novel liposome compositions
MY168791A (en) Carbamate compounds and of making and using same
MY180666A (en) Substituted pyrazolo [3,4-b] pyridines as medicaments
TW200606162A (en) Pyrazolopyridine derivatives
WO2011103460A8 (en) Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
TW200510392A (en) Chemical compounds
WO2007092620A3 (en) Stable formulations, and methods of their preparation and use
SG190042A1 (en) Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as jak inhibitors
TW200505452A (en) Chemical compounds
SG183817A1 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
MX346455B (en) Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis.
PH12019500804A1 (en) Liposomal formulation for use in the treatment of cancer
MX2009010165A (en) New imidazo[ 4,5-b]pyridine-7-carboxamides 704.
WO2013068565A3 (en) Melatonin-based solutions and powders for their preparation
IL209270A (en) Tricyclic nitrogen containing compounds and their use as antibacterials
WO2011009714A3 (en) Benzoquinolizinium salt derivatives as anticancer agents
MX336923B (en) Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts.
WO2010121675A3 (en) Thiazolyl-benzimidazoles
WO2011044375A3 (en) Apogossypolone derivatives as anticancer agents
UA93365C2 (en) Injectable preparations of diclofenic and its pharmaceutically acceptable salts, and processes for the preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11837250

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2816418

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011837250

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13881785

Country of ref document: US